Eli Lilly Cuts Prices For Weight Loss Drug Zepbound To $299 A Month As It Takes On Novo Nordisk’s Wegovy

• Through LillyDirect, self-paying patients can get Zepbound in doses ranging from 2.5 mg to 15 mg.
• The 5 mg dose has seen the largest price reduction, now available at $399 per month, down from $499.
• All other doses, including the entry-level 2.5 mg offering, have seen a price reduction of $50.

Eli Lilly & Co. (LLY) on Monday announced a price cut for its blockbuster weight-loss drug, Zepbound, as it looks to match a similar price cut announced by rival Novo Nordisk AS (NVO).

Lilly announced that single-dose vials of Zepbound will now be available starting at $299 per month for the 2.5 milligram dose, down from $349. Patients can buy Zepbound at these prices through the company’s direct-to-consumer platform, LillyDirect.

Eli Lilly shares were down nearly 1% in Monday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘bearish’ territory at the time of writing.

Updated Price List

Through LillyDirect, self-paying patients can get Zepbound in doses ranging from 2.5 mg to 15 mg.

The 5 mg dose has seen the largest price reduction. It is now available at $399 per month, down from $499. All other doses, including the entry-level 2.5 mg offering, have had their prices reduced by $50.

Notably, Zepbound doses of 7.5 mg to 15 mg will now cost $449 per month.

Taking On Wegovy

Lilly’s price cuts come weeks after Novo Nordisk announced a similar price cut for its obesity and diabetes drugs, Wegovy and Ozempic, respectively.

The Danish drugmaker announced in November that this offer applies to cash-paying patients seeking introductory doses of Wegovy and Ozempic. The company stated that patients can receive doses of 0.25 mg and 0.5 mg of the two drugs for $199 per month for two months. The offer is available from Nov. 17, 2025, to Mar. 31, 2026.

“We will keep working to provide more options – expanding choices for delivery devices and creating new pathways for access – so more people can get the medicines they need,” said Ilya Yuffa, executive vice president and president, Lilly USA and Global Customer Capabilities.

LLY stock is up 38% year-to-date and 34% over the past 12 months.

Also See: Kevin Hassett Leads Fed Chair Odds After Reportedly Saying He’d Be ‘Happy To Serve’, Trump Says His Mind Is Made Up

For updates and corrections, email newsroom[at]stocktwits[dot]com.